Pembrolizumab 면역치료를 시행 중인 비소세포성 폐암환자의 한방치료 증례보고
Traditional Korean Medicine for Non-Small Cell Lung Cancer Patient Undergoing Pembrolizumab Immunotherapy: A Case Report
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: The purpose of this study was to report the effect of traditional Korean medicine (TKM) in alleviating the side effects of lung cancer patient undergoing immunotherapy. Method: A 43-year-old man, who was diagnosed with non-small cell lung cancer, received pembrolizumab treatments. The patient was treated with acupuncture and herbal medicine (Geoeoyangpye-tang) to control various uncomfortable symptoms. The degree of pain was measured by the numeric rating scale (NRS). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) and the EORTC 13-item lung cancer-specific module (EORTC LC-13 questionnaire) were used to assess the change in the quality of life. Results: After the TKM treatment, the flank pain and arthralgia based on the NRS were significantly improved. Various uncomfortable symptoms such as fatigue, dyspnea, insomnia, and loss of appetite were also significantly improved, based on the EORTC QLQ-C30 and EORTC QLQ-LC13. The size of the primary tumor was decreased during treatment. The disease status was stable radiologically after two months from discharge.
Abstract
Objective: The purpose of this study was to report the effect of traditional Korean medicine (TKM) in alleviating the side effects of lung cancer patient undergoing immunotherapy. Method: A 43-year-old man, who was diagnosed with non-small cell lung cancer, received pembrolizumab treatments. The patient was treated with acupuncture and herbal medicine (Geoeoyangpye-tang) to control various uncomfortable symptoms. The degree of pain was measured by the numeric rating scale (NRS). The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire, Core 30 (EORTC QLQ-C30) and the EORTC 13-item lung cancer-specific module (EORTC LC-13 questionnaire) were used to assess the change in the quality of life. Results: After the TKM treatment, the flank pain and arthralgia based on the NRS were significantly improved. Various uncomfortable symptoms such as fatigue, dyspnea, insomnia, and loss of appetite were also significantly improved, based on the EORTC QLQ-C30 and EORTC QLQ-LC13. The size of the primary tumor was decreased during treatment. The disease status was stable radiologically after two months from discharge.
참고문헌 (28)
- World Cancer Report, "EB", ~ (2014)
- Schwartz AG, "Epidemiology of Lung Cancer", Advances in experimental medicine and biology, 893, pp.21~41 (2016)
- Horn L, "Harrison's Principles of Internal Medicine" (2015), McGraw-Hill Education
- Yun YH, "Validation of the Korean version of the EORTC QLQ-C30", Qual Life Res, 13(4), pp.863~868 (2004)
- Yu H, "PD-L1 Expression in Lung Cancer", J Thorac Oncol, 11(7), pp.964~975 (2016)
- Park SY, "Analysis of cutaneous adverse events of PD-1 inhibitors, Nivolumab and Pembrolizumab", Dept. of Social and Health Pharmacy, pp.2017
- Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer(KEYNOTE-010) : a randomised controlled trial", Lancet, 387(10027), pp.1540~1550 (2016)
- Herbst RS, "LBA63Long-term survival in patients(pts)with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab(pembro)", Annals of Oncology, 29(suppl_8) (2018)
- Sgambato A, "The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly", Expert opinion on biological therapy, 17(5), pp.565~571 (2017)
- Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", The New England journal of medicine, 372(21), pp.2018~2028 (2015)
- 이강욱, "Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer", Journal of Pharmacopuncture, 19(3), pp.259~263 (2016), 대한약침학회[DOI]
- Wu X, "Chinese Herbal Medicine for Improving Quality of Life Among Nonsmall Cell Lung Cancer Patients:Overview of Systematic Reviews and Network Meta-Analysis", Medicine, 95(1), pp.e2410~ (2016)
- Li TM, "Characteristics of Chinese herbal medicine usage and its effect on survival of lung cancer patients in Taiwan", Journal of ethnopharmacology, 213, pp.92~100 (2018)
- Seo HG, "A Case o f End-stage non-small cell Lung Cancer Patient with Brain Metastasis Treated with Pembro lizumab with Integrative Medicine Therapy", J of Kor Traditional Oncology, 23(2), pp.11~25 (2018)
- Institute NC, "Common Terminology Criteria for Adverse Events (CTCAE) v5.0", ~ (2017)
- Ryu HS, "A Survey on Korean Medicine Doctors for Cancer Symptoms Care in Korean Medicine Treatments", J of Kor Traditional Oncology, 22(1), pp.23~35 (2017)
- 류한성, "한방 치료에 대한 암 환자의 인식 조사 : 단면조사연구", 대한한방내과학회지, 38(3), pp.319~326 (2017), 대한한방내과학회
- Zhang LL, "Wang Xisheng Chief Physician's Experience in Treating Lung Cancer", Jounal of Shanxi College of Traditional Chinese Medicine, 33(4), pp.29~30 (2010)
- 한인선, "항암제로 유발된 백혈구감소증 회복에 미치는 황기의 효과", 대한한방내과학회지, 27(3), pp.579~588 (2006), 대한한방내과학회
- 이성옥, "백출 추출물의 암세포증식 저해 효과", 생약학회지, 36(3), pp.201~204 (2005), 한국생약학회
- 박가영, "Inhibitory Effect of Dendrobium moniliforme on NO and IL-1β Production in LPS-stimulated Macrophages", 한방안이비인후피부과학회지, 22(3), pp.11~19 (2009), 대한한방안이비인후피부과학회
- 박준홍, "桔梗의 適應免疫界 增强 效果", 대한한방부인과학회지, 23(4), pp.1~9 (2010), 대한한방부인과학회
- 이지영, "桔梗이 免疫活性 및 抗癌에 미치는 영향", 대한한방부인과학회지, 23(4), pp.10~19 (2010), 대한한방부인과학회
- 박신형, "A549 인체폐암세포에서 상백피 메틸렌클로라이드 추출물에 의한 Apoptosis 및 Autophagy 유발", 동의생리병리학회지, 24(6), pp.942~949 (2010), 한의병리학회
- 오명택, "玄胡索이 인체간암세포 증식억제 및 apoptosis 유발에 미치는 영향", 동의생리병리학회지, 21(6), pp.1437~1449 (2007), 한의병리학회
- Kasymjanova G, "The potential role for acupuncture in treating symptoms in patients with lung cancer : an observational longitudinal study", Curr Oncol, 20(3), pp.152~157 (2013)
- Minchom A, "A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma", Eur J Cancer, 61, pp.102~110 (2016)
- Belum VR, "Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor", Eur J Cancer, 60, pp.12~25 (2016)